With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The long-awaited Phase 3 CONVERT trial published this week in Lancet failed to show that once-daily radiation was superior to twice-daily radiation for limited-stage SCLC. Median overall survival did not significantly differ for the 547 patients randomized to 45 Gy / 20 delivered BID (30 months) vs 66 Gy / 33 delivered daily (25 months). Everyone received cisplatin/etoposide x 4-6 cycles, and the only difference in toxicity was an 11% increase in G4 neutropenia in the BID arm. This should squelch criticisms of the 1999 Turrisi trial which first established a survival benefit with the BID regimen, including the one about dose-insufficiency in the control arm. And with a trend towards better survival, BID radiation can finally feel confident with its standard-care-of designation. So take a long lunch-break, BID-radiation, you earned it.